Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 478 entries
Sorted by: Best Match Show Resources per page
Multifunctional nanomedicine platforms for cancer therapy.

Journal of nanoscience and nanotechnology

Zhang H.
PMID: 22852341
J Nanosci Nanotechnol. 2012 May;12(5):4012-8. doi: 10.1166/jnn.2012.6160.

Biocompatible nanomaterials have emerged as ideal platforms to develop multi-functionalization for achieving a compound effect using one system in which each component has a specially designed function. In this context, this article reviews multifunctional nanomedicine platforms for cancer therapy....

Cite
Zhang H. Multifunctional nanomedicine platforms for cancer therapy. J Nanosci Nanotechnol. 2012;12(5):4012-8doi: 10.1166/jnn.2012.6160.
Zhang, H. (2012). Multifunctional nanomedicine platforms for cancer therapy. Journal of nanoscience and nanotechnology, 12(5), 4012-8. https://doi.org/10.1166/jnn.2012.6160
Zhang, Haijun. "Multifunctional nanomedicine platforms for cancer therapy." Journal of nanoscience and nanotechnology vol. 12,5 (2012): 4012-8. doi: https://doi.org/10.1166/jnn.2012.6160
Zhang H. Multifunctional nanomedicine platforms for cancer therapy. J Nanosci Nanotechnol. 2012 May;12(5):4012-8. doi: 10.1166/jnn.2012.6160. PMID: 22852341.
Copy Download .nbib Format: NLM
Nanomedicine-based cancer targeting: a new weapon in an old war.

Nanomedicine (London, England)

McCarron PA, Faheem AM.
PMID: 20025458
Nanomedicine (Lond). 2010 Jan;5(1):3-5. doi: 10.2217/nnm.09.89.

No abstract available.

Cite
McCarron PA, Faheem AM. Nanomedicine-based cancer targeting: a new weapon in an old war. Nanomedicine (Lond). 2010;5(1):3-5doi: 10.2217/nnm.09.89.
McCarron, P. A., & Faheem, A. M. (2010). Nanomedicine-based cancer targeting: a new weapon in an old war. Nanomedicine (London, England), 5(1), 3-5. https://doi.org/10.2217/nnm.09.89
McCarron, Paul A, and Faheem, Ahmed Moustafa. "Nanomedicine-based cancer targeting: a new weapon in an old war." Nanomedicine (London, England) vol. 5,1 (2010): 3-5. doi: https://doi.org/10.2217/nnm.09.89
McCarron PA, Faheem AM. Nanomedicine-based cancer targeting: a new weapon in an old war. Nanomedicine (Lond). 2010 Jan;5(1):3-5. doi: 10.2217/nnm.09.89. PMID: 20025458.
Copy Download .nbib Format: NLM
The assessment of deaths after radiotherapy is an essential part of service evaluation—results of a 30 day mortality audit of patient deaths after palliative radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))

Boardman A, Clements H, Kellett D, Mitchell C, Board R.
PMID: 25262844
Clin Oncol (R Coll Radiol). 2014 Dec;26(12):807. doi: 10.1016/j.clon.2014.09.005. Epub 2014 Sep 26.

No abstract available.

Cite
Boardman A, Clements H, Kellett D, et al. The assessment of deaths after radiotherapy is an essential part of service evaluation—results of a 30 day mortality audit of patient deaths after palliative radiotherapy. Clin Oncol (R Coll Radiol). 2014;26(12):807doi: 10.1016/j.clon.2014.09.005.
Boardman, A., Clements, H., Kellett, D., Mitchell, C., & Board, R. (2014). The assessment of deaths after radiotherapy is an essential part of service evaluation—results of a 30 day mortality audit of patient deaths after palliative radiotherapy. Clinical oncology (Royal College of Radiologists (Great Britain)), 26(12), 807. https://doi.org/10.1016/j.clon.2014.09.005
Boardman, A, et al. "The assessment of deaths after radiotherapy is an essential part of service evaluation—results of a 30 day mortality audit of patient deaths after palliative radiotherapy." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. 26,12 (2014): 807. doi: https://doi.org/10.1016/j.clon.2014.09.005
Boardman A, Clements H, Kellett D, Mitchell C, Board R. The assessment of deaths after radiotherapy is an essential part of service evaluation—results of a 30 day mortality audit of patient deaths after palliative radiotherapy. Clin Oncol (R Coll Radiol). 2014 Dec;26(12):807. doi: 10.1016/j.clon.2014.09.005. Epub 2014 Sep 26. PMID: 25262844.
Copy Download .nbib Format: NLM
Putting molecular profiling to the test.

Cancer discovery

[No authors listed]
PMID: 25367966
Cancer Discov. 2014 Nov;4(11):OF4. doi: 10.1158/2159-8290.CD-NB2014-139. Epub 2014 Sep 18.

No abstract available.

Cite
Putting molecular profiling to the test. Cancer Discov. 2014;4(11):OF4doi: 10.1158/2159-8290.CD-NB2014-139.
(2014). Putting molecular profiling to the test. Cancer discovery, 4(11), OF4. https://doi.org/10.1158/2159-8290.CD-NB2014-139
"Putting molecular profiling to the test." Cancer discovery vol. 4,11 (2014): OF4. doi: https://doi.org/10.1158/2159-8290.CD-NB2014-139
Putting molecular profiling to the test. Cancer Discov. 2014 Nov;4(11):OF4. doi: 10.1158/2159-8290.CD-NB2014-139. Epub 2014 Sep 18. PMID: 25367966.
Copy Download .nbib Format: NLM
Targeted therapy: a sea change in the treatment of cancer.

Oncology (Williston Park, N.Y.)

Henderson IC.
PMID: 23330342
Oncology (Williston Park). 2012 Nov;26(11):1035, 1039.

No abstract available.

Cite
Henderson IC. Targeted therapy: a sea change in the treatment of cancer. Oncology (Williston Park). 2012;26(11):1035, 1039
Henderson, I. C. (2012). Targeted therapy: a sea change in the treatment of cancer. Oncology (Williston Park, N.Y.), 26(11), 1035, 1039.
Henderson, I Craig. "Targeted therapy: a sea change in the treatment of cancer." Oncology (Williston Park, N.Y.) vol. 26,11 (2012): 1035, 1039.
Henderson IC. Targeted therapy: a sea change in the treatment of cancer. Oncology (Williston Park). 2012 Nov;26(11):1035, 1039. PMID: 23330342.
Copy Download .nbib Format: NLM
Allocation of drugs in short supply.

The virtual mentor : VM

Johnson LM, Levine D.
PMID: 23937777
Virtual Mentor. 2013 Aug 01;15(8):645-8. doi: 10.1001/virtualmentor.2013.15.8.ecas2-1308.

No abstract available.

Cite
Johnson LM, Levine D. Allocation of drugs in short supply. Virtual Mentor. 2013;15(8):645-8doi: 10.1001/virtualmentor.2013.15.8.ecas2-1308.
Johnson, L. M., & Levine, D. (2013). Allocation of drugs in short supply. The virtual mentor : VM, 15(8), 645-8. https://doi.org/10.1001/virtualmentor.2013.15.8.ecas2-1308
Johnson, Liza-Marie, and Levine, Deena. "Allocation of drugs in short supply." The virtual mentor : VM vol. 15,8 (2013): 645-8. doi: https://doi.org/10.1001/virtualmentor.2013.15.8.ecas2-1308
Johnson LM, Levine D. Allocation of drugs in short supply. Virtual Mentor. 2013 Aug 01;15(8):645-8. doi: 10.1001/virtualmentor.2013.15.8.ecas2-1308. PMID: 23937777.
Copy Download .nbib Format: NLM
Revamping the clinical trials system.

Cancer discovery

[No authors listed]
PMID: 22586561
Cancer Discov. 2011 Aug;1(3):194. doi: 10.1158/2159-8290.CD-ND11-04.

No abstract available.

Cite
Revamping the clinical trials system. Cancer Discov. 2011;1(3):194doi: 10.1158/2159-8290.CD-ND11-04.
(2011). Revamping the clinical trials system. Cancer discovery, 1(3), 194. https://doi.org/10.1158/2159-8290.CD-ND11-04
"Revamping the clinical trials system." Cancer discovery vol. 1,3 (2011): 194. doi: https://doi.org/10.1158/2159-8290.CD-ND11-04
Revamping the clinical trials system. Cancer Discov. 2011 Aug;1(3):194. doi: 10.1158/2159-8290.CD-ND11-04. PMID: 22586561.
Copy Download .nbib Format: NLM
Optimizing cancer care: is the future bright?.

Clinical pharmacology and therapeutics

Zahedi P, De Souza R, Piquette-Miller M.
PMID: 21862960
Clin Pharmacol Ther. 2011 Sep;90(3):347-50. doi: 10.1038/clpt.2011.167.

No abstract available.

Cite
Zahedi P, De Souza R, Piquette-Miller M. Optimizing cancer care: is the future bright?. Clin Pharmacol Ther. 2011;90(3):347-50doi: 10.1038/clpt.2011.167.
Zahedi, P., De Souza, R., & Piquette-Miller, M. (2011). Optimizing cancer care: is the future bright?. Clinical pharmacology and therapeutics, 90(3), 347-50. https://doi.org/10.1038/clpt.2011.167
Zahedi, P, et al. "Optimizing cancer care: is the future bright?." Clinical pharmacology and therapeutics vol. 90,3 (2011): 347-50. doi: https://doi.org/10.1038/clpt.2011.167
Zahedi P, De Souza R, Piquette-Miller M. Optimizing cancer care: is the future bright?. Clin Pharmacol Ther. 2011 Sep;90(3):347-50. doi: 10.1038/clpt.2011.167. PMID: 21862960.
Copy Download .nbib Format: NLM
Emerging evidence on the pathobiology of mucositis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV.
PMID: 23604521
Support Care Cancer. 2013 Jul;21(7):2075-83. doi: 10.1007/s00520-013-1810-y. Epub 2013 Apr 21.

BACKGROUND: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely.METHODS: Panel...

Cite
Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013;21(7):2075-83doi: 10.1007/s00520-013-1810-y.
Al-Dasooqi, N., Sonis, S. T., Bowen, J. M., Bateman, E., Blijlevens, N., Gibson, R. J., Logan, R. M., Nair, R. G., Stringer, A. M., Yazbeck, R., Elad, S., Lalla, R. V. (2013). Emerging evidence on the pathobiology of mucositis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 21(7), 2075-83. https://doi.org/10.1007/s00520-013-1810-y
Al-Dasooqi, Noor, et al. "Emerging evidence on the pathobiology of mucositis." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 21,7 (2013): 2075-83. doi: https://doi.org/10.1007/s00520-013-1810-y
Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013 Jul;21(7):2075-83. doi: 10.1007/s00520-013-1810-y. Epub 2013 Apr 21. PMID: 23604521.
Copy Download .nbib Format: NLM
Pain at home. Implications for home care providers.

Caring : National Association for Home Care magazine

Ferrell BR, Patterson B.
PMID: 10315743
Caring. 1987 Nov;6(11):22-5.

No abstract available.

Cite
Ferrell BR, Patterson B. Pain at home. Implications for home care providers. Caring. 1987;6(11):22-5
Ferrell, B. R., & Patterson, B. (1987). Pain at home. Implications for home care providers. Caring : National Association for Home Care magazine, 6(11), 22-5.
Ferrell, B R, and Patterson, B. "Pain at home. Implications for home care providers." Caring : National Association for Home Care magazine vol. 6,11 (1987): 22-5.
Ferrell BR, Patterson B. Pain at home. Implications for home care providers. Caring. 1987 Nov;6(11):22-5. PMID: 10315743.
Copy Download .nbib Format: NLM
Cost-effectiveness of cancer chemotherapy: risks/benefit ratio--socio-economic and ethical considerations.

Cancer treatment reviews

Macdonald EA.
PMID: 3125970
Cancer Treat Rev. 1987 Dec;14(3):345-50. doi: 10.1016/0305-7372(87)90028-4.

No abstract available.

Cite
Macdonald EA. Cost-effectiveness of cancer chemotherapy: risks/benefit ratio--socio-economic and ethical considerations. Cancer Treat Rev. 1987;14(3):345-50doi: 10.1016/0305-7372(87)90028-4.
Macdonald, E. A. (1987). Cost-effectiveness of cancer chemotherapy: risks/benefit ratio--socio-economic and ethical considerations. Cancer treatment reviews, 14(3), 345-50. https://doi.org/10.1016/0305-7372(87)90028-4
Macdonald, E A. "Cost-effectiveness of cancer chemotherapy: risks/benefit ratio--socio-economic and ethical considerations." Cancer treatment reviews vol. 14,3 (1987): 345-50. doi: https://doi.org/10.1016/0305-7372(87)90028-4
Macdonald EA. Cost-effectiveness of cancer chemotherapy: risks/benefit ratio--socio-economic and ethical considerations. Cancer Treat Rev. 1987 Dec;14(3):345-50. doi: 10.1016/0305-7372(87)90028-4. PMID: 3125970.
Copy Download .nbib Format: NLM
Ensuring Patient Safety and Access in Cancer Care.

Journal of the National Comprehensive Cancer Network : JNCCN

Winckworth-Prejsnar K, Nardi EA, McCanney J, Stewart FM, Langbaum T, Gould BJ, Fitzgerald CL, Carlson RW.
PMID: 29223983
J Natl Compr Canc Netw. 2017 Dec;15(12):1460-1464. doi: 10.6004/jnccn.2017.7049.

The inability to obtain the right high-quality cancer care in a timely and safe manner can have devastating results for patients. As cancer care becomes inundated with cutting edge and novel treatments, such as personalized medicine, oral chemotherapy, biosimilars,...

Cite
Winckworth-Prejsnar K, Nardi EA, McCanney J, et al. Ensuring Patient Safety and Access in Cancer Care. J Natl Compr Canc Netw. 2017;15(12):1460-1464doi: 10.6004/jnccn.2017.7049.
Winckworth-Prejsnar, K., Nardi, E. A., McCanney, J., Stewart, F. M., Langbaum, T., Gould, B. J., Fitzgerald, C. L., & Carlson, R. W. (2017). Ensuring Patient Safety and Access in Cancer Care. Journal of the National Comprehensive Cancer Network : JNCCN, 15(12), 1460-1464. https://doi.org/10.6004/jnccn.2017.7049
Winckworth-Prejsnar, Katy, et al. "Ensuring Patient Safety and Access in Cancer Care." Journal of the National Comprehensive Cancer Network : JNCCN vol. 15,12 (2017): 1460-1464. doi: https://doi.org/10.6004/jnccn.2017.7049
Winckworth-Prejsnar K, Nardi EA, McCanney J, Stewart FM, Langbaum T, Gould BJ, Fitzgerald CL, Carlson RW. Ensuring Patient Safety and Access in Cancer Care. J Natl Compr Canc Netw. 2017 Dec;15(12):1460-1464. doi: 10.6004/jnccn.2017.7049. PMID: 29223983.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 478 entries